At one time or the other, we all need medical care. At such times, we find solace in knowing that there are proven medicine, to treat our illnesses and to back our very able doctors. However, we always forget to appreciate the people behind the research of these drugs. But if you did think of it, these ladies and gentlemen are crucial to the process. And, a perfect representation of this group is Scott Rocklage.
Scott Rocklage is an extraordinary man doing extra-ordinary things. He is currently the managing partner of 5AM Venture Management LLC, a position that he has held since the year 2004. This was a year after joining the company as a Venture Partner. Talking to Ideamensch, he told them that his company is named 5AM because that is early enough and they are in the business of forming companies, which is also known as early stage.
Also, he mentioned that in order to bring such ideas to life, he works with entrepreneurs. And, it is through calendaring, prioritization and management that he is able to get things done.
At 5AM, Scott Rocklage is able to lead efficiently because of his past experiences in leadership positions. In the past he worked for companies such as Nycomed Interventional Inc, where he was the President and Chief Executive Officer since the year 1992 to the year 1994. Learn more about Michael Lacey: http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/
While working for Nycomed Intervention, he simultaneously worked as the President and CEO of Nycomed Salutar Inc. He stayed in these positions from the year 1990 to the year 1994.
When he left the Nycomed group, he founded his own organization, Cubist Pharmaceuticals, where he was to work for the next 6 years. For the 6 years that he was with Cubist, he worked as the president of the company.
Rocklage has also worked in the board of directors for a number of companies in the life sciences industry. He gets these opportunities due to a successful education and career background. He is a graduate of the Massachusetts Institute of Technology, where he received his PHD in Chemistry.